A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer

被引：1

作者：

Yan, Min ^{[2
,3
]}

Yuan, Peng ^{[4
]}

Ouyang, Quchang ^{[5
]}

Cheng, Ying ^{[6
]}

Han, Guohui ^{[7
]}

Wang, Dewei ^{[8
]}

Ran, Li ^{[9
]}

Sun, Tao ^{[10
]}

Zhao, Da ^{[11
]}

Bai, Yuju ^{[12
]}

Yang, Shun'e ^{[13
]}

Wang, Xiaojia ^{[14
,15
]}

Wu, Rong ^{[16
]}

Zeng, Xiaohua ^{[17
]}

Yao, Herui ^{[18
]}

Ji, Xuening ^{[19
]}

Jiang, Jun ^{[20
]}

Hu, Xiaohua ^{[21
]}

Lin, Haifeng ^{[22
]}

Zheng, Liping ^{[23
]}

Zhu, Zhitu ^{[24
]}

Ge, Wei ^{[25
]}

Yang, Junlan ^{[26
]}

Cui, Tongjian ^{[27
]}

Zhang, Xiaozhi ^{[28
]}

Lu, Fangyang ^{[29
]}

Li, Wenhui ^{[30
]}

Xu, Hongyan ^{[31
]}

Kang, Mafei ^{[32
]}

Gong, Ping ^{[33
]}

Zou, Liqun ^{[34
]}

Liu, Jiang ^{[35
]}

Zhang, Hongliang ^{[36
]}

Yu, Hao ^{[37
]}

Xu, Binghe ^{[1
]}

机构：

[1] Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, 17 Panjiayuannanli, Beijing 100021, Peoples R China

[2] Zhengzhou Univ, Affiliated Canc Hosp, Henan Breast Canc Ctr, Dept Breast Dis, Zhengzhou, Henan, Peoples R China

[3] Henan Canc Hosp, Zhengzhou, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China

[5] Hunan Canc Hosp, Dept Breast Canc Med Oncol, Changsha, Peoples R China

[6] Canc Hosp Jilin Prov, Dept Oncol, Changchun, Peoples R China

[7] Shanxi Med Univ, Shanxi Prov Canc Hosp, Dept Breast Surg, Taiyuan, Peoples R China

[8] Hainan Gen Hosp, Dept Thorac Surg, Haikou, Hainan, Peoples R China

[9] Guizhou Med Univ, Guizhou Canc Hosp, Affiliated Hosp, Dept Oncol, Guiyang, Peoples R China

[10] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Med Oncol, Shenyang, Peoples R China

[11] Lanzhou Univ, Hosp 1, Dept Internal Med Oncol, Lanzhou, Peoples R China

[12] Zunyi Med Univ, Affiliated Hosp, Dept Oncol, Zunyi, Guizhou, Peoples R China

[13] Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Breast Canc & Lymphoma, Urumqi, Peoples R China

[14] Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Breast Med Oncol,Canc Hosp, Hangzhou, Peoples R China

[15] Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China

[16] China Med Univ, Shengjing Hosp, Dept Oncol, Shenyang, Peoples R China

[17] Chongqing Univ, Chongqing Canc Hosp, Breast Ctr, Chongqing, Peoples R China

[18] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, Guangzhou, Peoples R China

[19] Dalian Univ, Affiliated Zhongshan Hosp, Dept Oncol, Dalian, Peoples R China

[20] Gen Hosp Min Ind Grp Fuxin, Dept Surg Oncol, Fuxin, Peoples R China

[21] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Nanning, Peoples R China

[22] Hainan Med Univ, Affiliated Hosp 2, Dept Med Oncol, Haikou, Hainan, Peoples R China

[23] Hainan Med Univ, Affiliated Hosp, Dept Breast Thorac Tumor Surg, Haikou, Hainan, Peoples R China

[24] Jinzhou Med Univ, Affiliated Hosp 1, Canc Ctr, Jinzhou, Peoples R China

[25] Wuhan Univ, Renmin Hosp, Ctr Oncol, Wuhan, Peoples R China

[26] Peoples Liberat Army Gen Hosp, Dept Med Oncol, Beijing, Peoples R China

[27] Fujian Prov Hosp, Dept Oncol, Fuzhou, Peoples R China

[28] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Radiotherapy & Oncol, Xian, Peoples R China

[29] Guiyang Med Univ, Affiliated Hosp 2, Dept Oncol, Guiyang, Peoples R China

[30] Kunming Med Coll, Affiliated Hosp 3, Tumor Hosp Yunnan Prov, Dept Radiotherapy, Kunming, Yunnan, Peoples R China

[31] Jilin Second Peoples Hosp, Dept Oncol, Jilin, Jilin, Peoples R China

[32] Guilin Med Univ, Affiliated Hosp, Dept Med Oncol, Guilin, Peoples R China

[33] Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept Oncol, Shihezi, Peoples R China

[34] Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Peoples R China

[35] Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Oncol, Urumqi, Peoples R China

[36] Xinjiang Uygur Autonomous Reg Chinese Med Hosp, Dept Oncol, Urumqi, Peoples R China

[37] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Peoples R China

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2022年 / 14卷

关键词：

breast cancer; chemotherapy; efficacy; lobaplatin; neoplasm metastasis; safety; PLATINUM-BASED CHEMOTHERAPY; CISPLATIN; ANTHRACYCLINES; MONOTHERAPY;

D O I：

10.1177/17588359221122715

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Since lobaplatin (LBP) has been approved to treat metastatic breast cancer in China, this study aimed to evaluate the safety and efficacy of LBP-based chemotherapy in clinical practice. Methods: This trial was a prospective, open-label, multicenter phase IV clinical trial that enrolled patients with unresectable locally advanced or recurrent/metastatic breast cancer from 34 sites between July 2013 and March 2017. Patients were treated with LBP monotherapy or in combination for four to six cycles. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Results: A total of 1179 patients were analyzed; 59 (5.0%) were treated with LBP alone, 134 (11.4%) with LBP plus paclitaxel, 263 (22.3%) with LBP plus docetaxel, 237 (20.1%) with LBP plus gemcitabine, 403 (34.2%) with LBP plus vinorelbine, and 83 (7.0%) with other LBP-based regimens. The overall incidence of adverse events (AEs) was 95.2%, and 57.9% of patients had grade >3 AEs. The most common grade >3 AEs were neutropenia (43.9%), leukopenia (39.4%), anemia (17.8%), and thrombopenia (17.7%). LBP monotherapy showed the lowest incidence of grade >3 AEs (39.0%), followed by LBP plus docetaxel (52.9%), LBP plus paclitaxel (59.0%), LBP plus vinorelbine (62.5%), and LBP plus gemcitabine (62.9%). The ORR and DCR were 36.8 and 77.0%, respectively. The median PFS was 5.5 months (95% confidence interval: 5.2-5.9). Conclusion: LBP-based chemotherapy shows favorable efficacy in patients with advanced breast cancer, with manageable safety profile.

引用

页数：11

共 24 条

[1] Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis
Alsaloumi, Louai
Shawagfeh, Shaima
Abdi, Abdikarim
Basgut, Bilgen
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (12) : 694 - 702
[2] Breast Cancer Group Branch of Oncologist Chinese Medical Doctor Association, 2021, Zhonghua Zhong Liu Za Zhi, V43, P167, DOI 10.3760/cma.j.cn112152-20201012-00892
[3] Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China
Chen, Yimeng
Guan, Yin
Wang, Jiayu
Ma, Fei
Luo, Yang
Chen, Shanshan
Zhang, Pin
Li, Qing
Cai, Ruigang
Li, Qiao
Mo, Hongnan
Lan, Bo
Chen, Xuelian
Zhao, Weihong
Xu, Binghe
Fan, Ying
[J]. INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (12) : 3490 - 3499
[4] Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer
Cheng, Ying
Fan, Yun
Liu, Xiaoqing
Liu, Yunpeng
Liu, Jiwei
Wang, Dong
Yu, Yan
Qin, Shukui
Liu, Wei
Huang, Cheng
Zhang, Helong
Liang, Jun
Shi, Jianhua
Sheng, Lijun
Yu, Hao
[J]. ONCOLOGY LETTERS, 2019, 17 (05) : 4701 - 4709
[5] Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer
Chew, Helen K.
Doroshow, James H.
Frankel, Paul
Margolin, Kim A.
Somlo, George
Lenz, Heinz-Josef
Gordon, Michael
Zhang, Wu
Yang, Dongyun
Russell, Christy
Spicer, Darcy
Synold, Tim
Bayer, Robert
Hantel, Alexander
Stiff, Patrick J.
Tetef, Merry L.
Gandara, David R.
Albain, Kathy S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) : 2163 - 2169
[6] Platinum-based chemotherapy in metastatic breast cancer: current status
Decatris, MP
Sundar, S
O'Byrne, KJ
[J]. CANCER TREATMENT REVIEWS, 2004, 30 (01) : 53 - 81
[7] Platinum-based drugs: past, present and future
Dilruba, Shahana
Kalayda, Ganna V.
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1103 - 1124
[8] Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
Ho, Gwo Yaw
Woodward, Natasha
Coward, Jermaine I. G.
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 102 : 37 - 46
[9] TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Isakoff, Steven J.
Mayer, Erica L.
He, Lei
Traina, Tiffany A.
Carey, Lisa A.
Krag, Karen J.
Rugo, Hope S.
Liu, Minetta C.
Stearns, Vered
Come, Steven E.
Timms, Kirsten M.
Hartman, Anne-Renee
Borger, Darrel R.
Finkelstein, Dianne M.
Garber, Judy E.
Ryan, Paula D.
Winer, Eric P.
Goss, Paul E.
Ellisen, Leif W.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1902 - U67
[10] Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
Li, Meiying
Fan, Ying
Li, Qing
Zhang, Pin
Yuan, Peng
Ma, Fei
Wang, Jiayu
Luo, Yang
Cai, Ruigang
Chen, Shanshan
Li, Qiao
Xu, Binghe
[J]. MEDICINE, 2015, 94 (43)

← 1 2 3 →